The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a more substantial decrease in body weight and improve metabolic functio